Mind Medicine (MindMed) Inc. / Definium Therapeutics: Business Overview, Financials & Competitive Analysis
Mind Medicine (MindMed) Inc. / Definium Therapeutics scores 7/10 on the AskCyborg Cyborg Score (Strong). High-potential psychedelic therapeutics company with FDA breakthrough designation and multiple Phase 3 trials anticipated to deliver transformational clinical readouts in 2026. The company has secured $209.1M in cash and equivalents plus $242.8M from a recent offering, with guidance to fund operations into 2028. Phase 2b.
What is Mind Medicine (MindMed) Inc. / Definium Therapeutics's industry? Mind Medicine (MindMed) Inc. / Definium Therapeutics (mindmed.co) operates in Biopharmaceutical / Psychedelic-Inspired Therapeutics / Clinical-Stage Drug Development. AskCyborg classifies Mind Medicine (MindMed) Inc. / Definium Therapeutics under Biopharmaceutical / Psychedelic-Inspired Therapeutics / Clinical-Stage Drug Development in its company registry.
Mind Medicine is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders by targeting neurotransmitter pathways that play key roles in brain health. The comp...
Cyborg Score thesis
High-potential psychedelic therapeutics company with FDA breakthrough designation and multiple Phase 3 trials anticipated to...
Read the full analyst-debate transcript →Get the Latest Mind Medicine (MindMed) Inc. / Definium Therapeutics Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMind Medicine (MindMed) Inc. / Definium Therapeutics Overview
Pro stress-test →Mind Medicine is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders by targeting neurotransmitter pathways that play key roles in brain health. The company's lead candidate MM120 (LSD) has received FDA Breakthrough Therapy Designation for generalized anxiety disorder, with approximately half of trial participants experiencing significant symptom relief.
Strategic Profile
Pro stress-test →The company's mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. 2026 is positioned as a transformational year with accelerated Phase 3 data readout from the Emerge MDD trial expected in mid-2026 and plans to initiate Ascend, a second Phase 3 MDD study.
Competitive Landscape
Pro stress-test →The company is positioning itself as a leader in late-stage psychiatric drug development with MM120 ODT (formerly DT120) for GAD and MDD, competing in the psychedelic-inspired therapeutics space targeting psychiatric and neurological disorders. Key competitors include Compass Pathways (psilocybin for treatment-resistant depression) and other emerging psychedelic biotech firms pursuing FDA approvals in psychiatry.
Industry Context
Mind Medicine (MindMed) Inc. / Definium Therapeutics operates in Biopharmaceutical / Psychedelic-Inspired Therapeutics / Clinical-Stage Drug Development.
Key facts
Founded: 2019 · Headquarters: New York, US · Revenue: $0 · Market cap: $1.15B